Citations

Clear

3138 citation(s) found for "Smith, AM".

64: FACTORS PREDICTING KIDNEY TRANSPLANT RECIPIENT ADMISSION TO THE ICU: A 10-YEAR SINGLE-CENTER STUDY
Abrol, Nitin , Taner, Timuçin , Smith, Byron H. , Kashyap, Rahul , Iyer, Vivek

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 32-32

10.1097/01.ccm.0000618756.22274.16 Get It

Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families
Yang, Xin , Doroszuk, Alicja, Schneider, Sandra , Allen, Jamie , Decker, Brennan , Redman, James , Scarth, James A. , Plaskocinska, Inga, Luccarini, Craig , Shah, Mitul , Pooley, Karen A. , Dorling, Leila , Lee, Andrew , Adank, Muriel A. , Aittomäki, Kristiina, Andrulis, Irene L. , Ang, Peter , Bernstein, Jonine L. , Bobolis, Kristie, Borg, Åke , Blomqvist, Carl , Claes, Kathleen , Cuggia, Adeline , Culver, Julie O. , Damiola, Francesca , Pauw, Antoine De , Dolinsky, Jill S. , Engel, Christoph , Evans, D. Gareth , Goode, Ellen L. , Gruber, Stephen B., Hahnen, Eric , Hake, Christopher R., Heikkinen, Tuomas , Hurley, Judith , Janavičius, Ramūnas , Kleibl, Zdeněk , Kleiblová, Petra , Konstantopoulou, Irene , Kvist, Anders , LaDuca, Holly , Lee, Ann S. G. , Lesueur, Fabienne , Mannermaa, Arto, Manoukian, Siranoush , McFarland, Rachel, McKinnon, Wendy, Meindl, Alfons , Metcalfe, Kelly , Taib, Nur Aishah Mohd , Moilanen, Jukka S. , Nathanson, Katherine L. , Ng, Pei Sze , Nguyen‐Dumont, Tú , Nielsen, Sarah M. , Obermair, Florian , Offit, Kenneth, Olopade, Olufunmilayo I. , Ottini, Laura , Penkert, Judith , Pylkäs, Katri , Ramus, Susan J. , Rudaitis, Vilius , Side, Lucy, Silva‐Smith, Rachel , Silvestri, Valentina , Skytte, Anne‐Bine , Slavin, Thomas, Soukupová, Jana , Trainer, Alison H., Unzeitig, Gary, Usha, Lydia , Hansen, Thomas van Overeem , Whitworth, James , Wood, Marie , Yip, Cheng Har , Yoon, Sook‐Yee , Yussuf, Amal , Zogopoulos, George , Goldgar, David E. , Chenevix‐Trench, Georgia , George, Sophia , Houdayer, Claude , James, Paul A. , El-Haffaf, Zaki, Ehrencrona, Hans , Janatová, Markéta , Peterlongo, Paolo , Nevanlinna, Heli, Schmutzler, Rita K., Teo, Soo‐Hwang , Weitzel, Jeffrey N. , Elliott, Aaron , Winqvist, Robert , Easton, Douglas F. , Antoniou, Antonis C. , Houdayer, Claude , James, Paul , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Teo, Soo H , Weitzel, Jeffrey N , Claes, Kathleen B M , Ehrencrona, Hans , Evans, D Gareth , Konstantopoulou, Irene , Olopade, Olufunmilayo I , Silvestri, Valentina , Nathanson, Katherine L , Engel, Christoph , Nguyen-Dumont, Tu , Chenevix-Trench, Georgia , Ottini, Laura , Metcalfe, Kelly A , Pylkäs, Katri , Janatova, Marketa , Soukupova, Jana , Hansen, Thomas van Overeem , Kleibl, Zdenek , Manoukian, Siranoush , Mohd Taib, Nur Aishah , Decker, Brennan , Leslie, Goska , Dunning, Alison M. , Adlard, Julian , Barwell, Julian , CONCANNON, PATRICK J. , Dı́ez, Orland , Domchek, Susan M. , Fostira, Florentia , Garber, Judy E. , Golmard, Lisa , Maher, Eamonn R. , Mannermaa, Arto, Meindl, Alfons , Neuhausen, Susan L. , Radice, Paolo , Slavin, Thomas P. , Tondini, Carlo Alberto , Hopper, John L. , Pharoah, Paul D.P. , Balmañà, Judith , El-Haffaf, Zaki, Nevanlinna, Heli , Robson, Mark E. , Pal, Tuya , Couch, Fergus J. , Southey, Melissa C. , Foulkes, William D. , Tischkowitz, Marc D.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2019 | Volume: 38 | Issue: 7 | Pages: 674-685

10.1200/jco.19.01907 | PMID 31841383 Get It

PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized.METHODSWe analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.RESULTSWe found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10−76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10−3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10−3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10−2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age ( P for trend = 2.0 × 10−3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies ( P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.CONCLUSIONThese results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Proceedings From the Ice Hockey Summit III: Action on Concussion
Smith, Aynsley M., Alford, Patrick A., Aubry, Mark, Benson, Brian W., Brooks, Alison, Burke, Charles J., Eaves, Michael, Eickhoff, Chad, Erredge, Kristen, Fraser, Douglas D. , Giza, Christopher C. , Greenwald, Richard M., Hoshizaki, Blaine, Huston, John , Jorgensen, Janelle, Joyner, Michael J. , Leaf, Matthew, Leddy, John J. , Margarucci, Kevin, Munce, Thayne A. , Prideaux, Cara C. , Roberts, William O. , Shen, Francis X. , Soma, David , Tabrum, Mark, Stuart, Michael, Wethe, Jennifer V. , Whitehead, James R., Wiese‐Bjornstal, Diane M. , Dodick, David, Finnoff, Jonathan, Joyner, Michael, Krause, David, Prideaux, Cara, Wethe, Jennifer, Joyner, Michael J , Wethe, Jennifer V , Alford, Patrick W. , Black, Amanda M. , D’Arcy, Ryan C.N. , Dodick, David W. , Farrell, Kyle , Finnoff, Jonathan T. , Krause, David A. , LaVoi, Nicole M. , Margulies, Susan Sheps , Mihalik, Jason P. , Oeur, Anna , Stuart, Michael J.

Mayo Clinic

Clinical Journal of Sport Medicine | December 16, 2019 | Volume: 31 | Issue: 3 | Pages: e150-e160

10.1097/jsm.0000000000000745 | PMID 31842055 Get It

Objectives: The Ice Hockey Summit III provided updated scientific evidence on concussions in hockey to inform these 5 objectives: (1) describe sport related concussion (SRC) epidemiology; (2) classify prevention strategies; (3) define objective, diagnostic tests; (4) identify treatment; and (5) integrate science and clinical care into prioritized action plans and policy. Methods: Our action plan evolved from 40 scientific presentations. The 155 attendees (physicians, athletic trainers, physical therapists, nurses, neuropsychologists, scientists, engineers, coaches, and officials) voted to prioritize these action items in the final Summit session. Results: To (1) establish a national and international hockey database for SRCs at all levels; (2) eliminate body checking in Bantam youth hockey games; (3) expand a behavior modification program (Fair Play) to all youth hockey levels; (4) enforce game ejection penalties for fighting in Junior A and professional hockey leagues; (5) establish objective tests to diagnose concussion at point of care; and (6) mandate baseline testing to improve concussion diagnosis for all age groups. Conclusions: Expedient implementation of the Summit III prioritized action items is necessary to reduce the risk, severity, and consequences of concussion in the sport of ice hockey.
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
Marcath, Lauren A. , Vangipuram, Kiran, Gersch, Christina L. , Rae, James M. , Burness, Monika L. , Griggs, Jennifer J. , Poznak, Catherine Van , Hayes, Daniel F. , Henry, N. Lynn , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Henry, N Lynn , Kidwell, Kelley M. , Lavoie Smith, Ellen M

Mayo Clinic

British Journal of Clinical Pharmacology | December 11, 2019 | Volume: 86 | Issue: 5 | Pages: 880-890

10.1111/bcp.14192 | PMID 31823378 Get It

AimsChemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold).MethodsGermline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8‐item sensory subscale (CIPN8) of the patient‐reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN‐related treatment disruption.ResultsEPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β‐coefficient = 0.39, 95% confidence interval 0.11–0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild‐type (13.6 h) patients. Total number of missense variants (median = 0, range 0–2) was associated with decreased PN sensitivity (β‐coefficient: −0.42, 95% confidence interval −0.72 to −0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683.ConclusionIsolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.
Competency‐Based Assessment Tool for Pediatric Tracheotomy: International Modified Delphi Consensus
Propst, Evan J. , Wolter, Nikolaus E. , Ishman, Stacey L. , Balakrishnan, Karthik , Deonarain, Ashley R. , Mehta, Deepak, Zalzal, George H., Pransky, Seth M. , Roy, Soham , Myer, Charles M. , Torre, Michele , Johnson, Romaine F. , Lüdemann, Jeffrey P. , Derkay, Craig S. , Hong, Paul , Molter, David, Prager, Jeremy D. , Nguyen, Lily H. P. , Rutter, Michael J. , Zur, Karen B. , Sidell, Douglas R. , Johnson, Liane B. , Cotton, Robin T., Willging, J. Paul, Zdanski, Carlton J. , Manoukian, John J. , Lam, Derek J. , Gantwerker, Eric A. , Husein, Murad , Inglis, Andrew F., Green, Glenn E. , Javia, Luv, Schraff, Scott A. , Soma, Marlene , Deutsch, Ellen S. , Sobol, Steven E., Ida, Jonathan B., Choi, Sukgi S. , Uwiera, Trina C., Shah, Udayan K. , White, David R. , Wootten, Christopher T. , El‐Hakim, Hamdy , Bromwich, Matthew, Richter, Gresham T. , Vijayasekaran, Shyan , Smith, Marshall E. , Vaccani, Jean‐Philippe , Hartnick, Christopher J. , Faucett, Erynne A. , Sidell, Douglas R. , Hong, Paul , Prager, Jeremy D , Nguyen, Lily H P , Zur, Karen , Sidell, Douglas R , Hart, Catherine K , Gantwerker, Eric A , Husein, Murad , Choi, Sukgi , Hartnick, Christopher J , Faucett, Erynne A , Johnson, Romaine F , Sidell, Douglas R , Ishman, Stacey L , Lam, Derek J , Balakrishnan, Karthik , Chun, Robert H. , Hart, Catherine K. , Bauman, Nancy M.

Mayo Clinic

The Laryngoscope | December 10, 2019 | Volume: 130 | Issue: 11 | Pages: 2700-2707

10.1002/lary.28461 | PMID 31821571 Get It

Objectives/HypothesisCreate a competency‐based assessment tool for pediatric tracheotomy.Study DesignBlinded, modified, Delphi consensus process.MethodsUsing the REDCap database, a list of 31 potential items was circulated to 65 expert surgeons who perform pediatric tracheotomy. In the first round, items were rated as “keep” or “remove,” and comments were incorporated. In the second round, experts were asked to rate the importance of each item on a seven‐point Likert scale. Consensus criteria were determined a priori with a goal of 7 to 25 final items.ResultsThe first round achieved a response rate of 39/65 (60.0%), and returned questionnaires were 99.5% complete. All items were rated as “keep,” and 137 comments were incorporated. In the second round, 30 task‐specific and seven previously validated global rating items were distributed, and the response rate was 44/65 (67.7%), with returned questionnaires being 99.3% complete. Of the Task‐Specific Items, 13 reached consensus, 10 were near consensus, and 7 did not achieve consensus. For the 7 previously validated global rating items, 5 reached consensus and two were near consensus.ConclusionsIt is feasible to reach consensus on the important steps involved in pediatric tracheotomy using a modified Delphi consensus process. These items can now be considered to create a competency‐based assessment tool for pediatric tracheotomy. Such a tool will hopefully allow trainees to focus on the important aspects of this procedure and help teaching programs standardize how they evaluate trainees during this procedure.Level of Evidence5 Laryngoscope, 130:2700–2707, 2020
Clinical Massively Parallel Sequencing
Smith, David I, Gao, Ge , Smith, David I

Mayo Clinic

Clinical Chemistry | December 6, 2019 | Volume: 66 | Issue: 1 | Pages: 77-88

10.1373/clinchem.2019.303305 | PMID 31811004 Get It

Abstract BACKGROUND The newest advances in DNA sequencing are based on technologies that perform massively parallel sequencing (MPS). Since 2006, the output from MPS platforms has increased from 20 Mb to >7 Tb. First-generation MPS platforms amplify individual DNA molecules to multiple copies and then interrogate the sequence of those molecules. Second-generation MPS analyzes single unamplified molecules to generate much longer sequence reads but with less output than first-generation MPS and lower first-pass accuracy. With MPS technologies, it is now possible to analyze genomes, exomes, a defined subset of genes, transcriptomes, and even methylation across the genome. These technologies have and will continue to completely transform the clinical practice. CONTENT The major first- and second-generation MPS platforms and how they are used in clinical practice are discussed. SUMMARY The ability to sequence terabases of DNA per run on an MPS platform will dramatically change how DNA sequencing is used in clinical practice. Currently, MPS of targeted gene panels is the most common use of this technology clinically, but as the cost for genome sequencing inches downward to $100, this may soon become the method of choice (with the caveat that, at least in the near term, clinical-grade genome sequencing with interpretation may cost much more than $100). Other uses of this technology include sequencing of a mixture of bacterial and viral species (metagenomics), as well as the characterization of methylation across the genome.
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, Timothy D. , Lin, Daniel W. , Aggarwal, Rahul , Chism, David D. , Cost, Nicholas G. , Derweesh, Ithaar , LaGrange, Chad A. , Levine, Ellis , Longo, Thomas A., Lowrance, Will, Rais‐Bahrami, Soroush , Sircar, Kanishka , Smith, David C. , Tzou, Katherine S., Vaena, Daniel A. , Vaughn, David J. , Yamzon, Jonathan , Johnson-Chilla, Alyse, Keller, Jennifer , Pluchino, Lenora A. , Tzou, Katherine, Emamekhoo, Hamid , Feldman, Darren Richard , Geynisman, Daniel M. , Hancock, Steven Lee , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Saylor, Philip J. , Yamoah, Kosj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1529-1554

10.6004/jnccn.2019.0058 | PMID 31805523 Get It

Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nerve-sparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with >50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.
Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies
Low, Christopher M. , Keogh, Karina A., Saba, Elias S. , Gruszczynski, Nelson , Berti, Alvise , Baqir, Misbah , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , Gruszczynski, Nelson R, Choby, Garret , O'Brien, Erin K , Berti, Alvise , Specks, Ulrich , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | December 3, 2019 | Volume: 10 | Issue: 2 | Pages: 217-222

10.1002/alr.22503 | PMID 31793227 Get It

BackgroundIn this study we aim to describe presenting characteristics and identify prognostic factors for disease resolution in patients with chronic rhinosinusitis (CRS) in the setting of eosinophilic granulomatosis with polyangiitis (EGPA).MethodsPatients evaluated at a tertiary care center with diagnoses of EGPA and CRS were identified. Descriptive statistics were obtained. Univariate analysis was used to search for prognostic factors associated with higher Lund‐Mackay score at presentation and disease resolution.ResultsForty‐four patients were included with a mean age of 52.7 (standard deviation, 14) years. Twenty‐one patients (47.7%) were female, all had a diagnosis of asthma, and 36 (83.7%) had eosinophils >10%. Common presenting symptoms for CRS included nasal discharge (87.9%) followed by nasal congestion (83.9%) and facial pain and pressure (83.8%). Medical management of CRS included systemic corticosteroids (93.2%) and systemic antibiotics (75%). Surgical intervention occurred in 29 patients (67%). Nine patients (20.5%) had resolution of sinus symptoms, including 4 with imaging confirmation. Fourteen patients (31.8%) had continued CRS, but with improved symptoms, whereas 9 patients (20.5%) had continued CRS with no improvement in symptoms. Eleven patients (25%) were lost to follow‐up and 4 (9.1%) died. Univariate analysis did not show antineutrophil cytoplasmic antibody positivity, presence of peripheral eosinophilia, gender, age, or absence of systemic therapy to be predictive of higher Lund‐Mackay score at presentation or predictive of disease resolution.ConclusionCRS in patients with EGPA is often refractory to medical and surgical management. Treatment of these patients should occur in a multidisciplinary setting.
Triptan and ergotamine overdoses in the United States
Robblee, Jennifer , Butterfield, Richard , Kang, A. Min , Robblee, Jennifer V , Butterfield, Richard J, Smith, Jonathan H.

Mayo Clinic

Neurology | December 3, 2019 | Volume: 94 | Issue: 14 | Pages: No page available

10.1212/wnl.0000000000008685 | PMID 31792093 Get It

The effect of galvanic vestibular stimulation on distortion product otoacoustic emissions
Cevette, Michael J. , Cocco, Daniela , Pradhan, Gaurav N. , Galea, Anna M., Wagner, Linsey S., Oakley, Sarah R., Smith, Benn E., Zapala, David A., Brookler, Kenneth H. , Pradhan, Gaurav N , Stepánek, Jan

Mayo Clinic

Journal of Vestibular Research | December 2, 2019 | Volume: 22 | Issue: 1 | Pages: 17-25

10.3233/ves-2012-0444 | PMID 22699149 Get It

Galvanic stimulation has long been used as a nonmechanical means of activating the vestibular apparatus through direct action on the vestibular nerve endings. This stimulation has been reported to be safe, but no studies have examined the potential changes in the corresponding cochlear receptors. The aim of the present study was to evaluate the effect of galvanic vestibular stimulation (GVS) on distortion product otoacoustic emissions (DPOAEs). Fourteen subjects underwent DPOAEs during several conditions of GVS. The DPOAEs ranged from ∼ 1 kHz to ∼ 8 kHz at 65/55 dB for f1/f2 and with an f2/f1 ratio of 1.2. The subjects were evaluated at 10 stimulation conditions that ranged from −2.0 mA to +2.0 mA for each frequency. Statistical analysis showed no significant differences in DPOAE amplitudes for all conditions with and without GVS. Results also showed no significant differences between DPOAE amplitudes before and after GVS. Multivariate analysis found subject variability in DPOAE amplitude, which was not thought to be GVS related. Results indicated that GVS produced neither temporary nor permanent changes in DPOAEs.